BCM
QTTB icon

BML Capital Management’s Q32 Bio QTTB Stock Holding History

BML Capital Management’s Portfolio QTTB Stock Details QTTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-24,894
Closed -$424K – 31
2024
Q1 		$424K Sell
24,894
-16,668
-40% -$230K 0.28% 30
2023
Q4 		$455K Buy
+41,562
New +$608K 0.34% 32

Other funds holding QTTB

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

BML Capital Management's QTTB Position: Q2 2024 in Review

BML Capital Management sold out of Q32 Bio (QTTB) in Q2 2024, closing a stake of 24,894 shares — an estimated $424K sold.

BML Capital Management first reported a position in QTTB in Q4 2023 and held it in 2 quarters. The position peaked at $455K in Q4 2023. 54 funds tracked by Wall St. Rank hold QTTB as of Q2 2024.

  • BML Capital Management reported no remaining Q32 Bio position as of Q2 2024 after selling out during the quarter.
  • BML Capital Management sold 24,894 Q32 Bio shares in Q2 2024, an estimated $424K.
  • BML Capital Management first reported a position in Q32 Bio in Q4 2023 and held it in 2 quarters.
  • BML Capital Management's Q32 Bio position peaked at $455K in Q4 2023.
  • 54 funds tracked by Wall St. Rank held Q32 Bio as of Q2 2024.

Based on BML Capital Management's 13F filing for Q2 2024, filed 7 Aug 2024.